Triptans for Psoriasis Treatment via Topical Application
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis are partially effective but come with undesirable side effects, lack rapid action, and are not suitable for long-term use, especially for women of childbearing age or during lactation, and do not address the need for a topical solution without retinoid and steroid side effects.
Innovation Solution
The use of tryptamine-based drugs acting as 5-hydroxytryptamine-1 inhibitors, such as triptans, in topical formulations like creams, gels, or ointments, applied directly to the skin in concentrations between 0.001% and 1%, which are surprisingly effective in reducing psoriasis symptoms without the common side effects of systemic treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current topical treatments (steroids, Vitamin D3 analogues, Vitamin A derivatives) are used to treat psoriasis, then some therapeutic effect is achieved, but numerous undesirable side effects occur including steroidal side effects, irritant effects, and teratogenic effects
Solution Approach 1:
The patent changes the pharmacological parameter from conventional psoriasis treatments (steroids, retinoids, vitamin D analogues) to triptans (5-HT1B/1D receptor agonists). This parameter change allows achieving therapeutic effect through a different mechanism of action that does not trigger the harmful side effects associated with conventional treatments, including no teratogenic effects and no local irritation
Solution Approach 2:
The patent applies the mechanism of action of triptans (originally developed for migraine treatment) to psoriasis treatment. By copying the therapeutic approach from one disease area to another, the patent achieves psoriasis treatment without the side effects characteristic of conventional psoriasis medications
2Reliability
If systemic treatments (cyclosporine A, methotrexate, acitretin, biological treatments) are administered to treat moderate to severe psoriasis, then therapeutic efficacy is improved, but severe immunologic side effects, tumors, immunologic suppression, and long-term safety issues occur
Solution Approach 1:
The patent extracts the therapeutic benefit from triptans while eliminating the need for systemic administration. By applying triptans topically, the patent achieves local treatment efficacy without the severe systemic immunologic side effects and long-term safety issues associated with oral or injective systemic treatments
Solution Approach 2:
The patent uses topical application as an intermediary route of administration. This intermediary approach delivers the active compound locally to the skin lesions, achieving therapeutic efficacy while avoiding the severe systemic side effects that would result from oral or injective administration of immunosuppressive agents
3Reliability
If phototherapy (UVB and PUVA) is used to treat psoriasis, then therapeutic effect is achieved, but potentially carcinogenic radiation exposure occurs
Solution Approach 1:
The patent substitutes the physical/energetic mechanism of phototherapy (ultraviolet radiation) with a pharmacological mechanism (triptan receptor agonism). This substitution achieves therapeutic effect through chemical interaction with 5-HT1B/1D receptors rather than through potentially carcinogenic electromagnetic radiation
4Reliability
If local sensitizers such as Dithranol are used to treat psoriasis, then therapeutic effect is achieved, but severe irritation occurs limiting use to short duration
Solution Approach 1:
The patent changes the pharmacological parameter from local sensitizers (which work through irritation and inflammation) to triptans (which work through 5-HT1B/1D receptor agonism). This parameter change maintains therapeutic efficacy while eliminating severe local irritation, allowing for sustained long-term use without the time limitation imposed by irritant-based treatments
Data Source
AI summary
The present invention provides for a composition comprising a tryptamine based drug that acts as a 5-hydroxytryptamine-1 inhibitor in an amount sufficient to reduce the effects of psoriasis and wherein the composition is formulated for topical or oral administration.